GRIT Biotechnology
Shanghai
About GRIT Biotechnology
GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $153.5M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2025)
- Website: grit-bio.com
Industries & Categories
Biotechnology, Health Care, Medical Device
Canonical: https://fsome.com/organization/grit-biotechnology-82898 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.